3月13日 - ** 药物开发商CervoMed CRVO.O股价上涨4.4%至6.44美元
** 券商Jones Research将CRVO的评级从 "持有 "上调至 "买入"，维持15美元的目标价。
** 周一，CRVO宣布其药物neflamapimod在路易体痴呆症患者中的研究结果呈阳性，$(DLB)$。
** 研究数据提振了投资者的信心，我们看到，netlamapimod在路易体痴呆症患者中的下一步治疗中将采用更注重风险的方法。
** DLB是一种痴呆症，是由于大脑神经细胞中被称为路易体的蛋白质沉积物堆积所致。
** 截至周三收盘，该公司股价累计上涨 176.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.